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Abstract
Background: It has been shown that plasma carnitine concentrations decrease markedly during gestation. A recent 
study performed with a low number of subjects suggested that this effect could be due to a low iron status which 
leads to an impairment of carnitine synthesis. The present study aimed to confirm this finding in a greater number of 
subjects. It was moreover intended to find out whether low carnitine concentrations during pregnancy could be due 
to a reduced availability of precursors of carnitine synthesis, namely trimethyllysine (TML) and γ-butyrobetaine (BB).
Methods: Blood samples of 79 healthy pregnant women collected at delivery were used for this study.
Results: There was only a weak, non-significant (P > 0.05), correlation between plasma concentration of ferritin and 
those of free and total carnitine. There was no correlation between other parameters of iron status (plasma iron 
concentration, hemoglobin, MCV, MCH) and plasma concentration of free and total carnitine. There were, however, 
significant (P < 0.05) positive correlations between concentrations of TML and BB and those of free and total carnitine 
in plasma.
Conclusions: The results of this study suggest that an insufficient iron status is not the reason for low plasma carnitine 
concentrations observed in pregnant women. It is rather indicated that low plasma carnitine concentrations are 
caused by a low availability of precursors for carnitine synthesis during gestation.
Background
Carnitine (L-3-hydroxy-4-N-N-N-trimethylaminobu-
tyrate) is an essential metabolite, which has a number of
indispensable functions in intermediary metabolism. The
most prominent function lies in its role in the transport
of activated long-chain fatty acids from the cytosol to the
mitochondrial matrix where β-oxidation takes place.
Other functions of carnitine include the transfer of prod-
ucts of peroxisomal β-oxidation to the mitochondria for
oxidation in the citrate cycle, the modulation of the acyl-
CoA/CoA-ratio and the storage of energy as acetylcarni-
tine [1-3]. All tissues that use fatty acids as a fuel source
require carnitine for normal function. Carnitine is
derived from dietary sources and endogenous biosynthe-
sis [4,5]. Carnitine biosynthesis involves a complex series
of reactions involving several tissues [6]. Lysine provides
the carbon backbone of carnitine. Lysine in protein pep-
tide linkages undergoes methylation of the ε-amino group
to yield trimethyllysine (TML), which is released upon
protein degradation. The released TML is further oxi-
dised to γ-butyrobetaine (BB) by the action of trimeth-
yllysine dioxygenase (TMLD), 3-hydroxy-N-
trimethyllysine aldolase and 4-N-trimethylaminobutyral-
dehyde dehydrogenase (TMABA DH). BB is hydroxylated
by γ-butyrobetaine dioxygenase (BBD) to form carnitine.
In humans, this last reaction occurs primarily in liver and
kidney [6]. Previous studies have shown that the availabil-
ity of BB is limiting for carnitine synthesis while the activ-
ity of BBD is normally in excess of the amount of
carnitine formed [7].
In non-pregnant, fertile women average plasma total
carnitine concentration is around 40 μmol/L [8,9]. Dur-
ing gestation, plasma carnitine concentrations are
strongly decreasing. At the time of delivery, plasma carni-
tine concentrations are decreased to about half of the
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concentrations of non-pregnant women [8-14], even
though dietary carnitine intake increases as gestation
proceeds [15]. Similar low carnitine concentrations are
only found in patients with carnitine deficiency [16]. It is
unclear whether such low carnitine concentrations in
pregnant women have adverse effects on their metabo-
lism or on the metabolism of the fetus. Nevertheless, due
to the important functions of carnitine, it is possible that
the low carnitine status during gestation could have bene-
ficial effects on pregnant women and their fetuses.
The reasons for these low plasma carnitine concentra-
tions are currently largely unknown. Recently, we investi-
gated the effect of supplementation of carnitine during
pregnancy on plasma carnitine concentrations [14]. In
that study, we observed also a positive relationship
between parameters of iron status (MCV, MCH, ferritin)
and plasma carnitine concentration in the control group
consisting of 13 pregnant women. This relationship
seems plausible as two enzymes involved in carnitine syn-
thesis, namely TMLD and BBD, contain iron with a cata-
lytic function [17,18]. Hence, we suggested that low
plasma carnitine concentrations are caused by a reduced
carnitine synthesis due to a reduced activity of iron-
dependent enzymes involved in carnitine synthesis. How-
ever, the low number of subjects considered in this study
constitutes a clear limitation for the validity of the rela-
tionship between iron and carnitine in pregnant women.
In order to confirm a possible role of the iron status for
plasma carnitine concentrations during gestation, we
examined in the present study parameters of iron status
and carnitine concentrations in plasma of 79 women at
delivery. To find out whether a reduced availability of
metabolic precursors could be limiting for carnitine syn-
thesis, we determined also the concentrations of BB and
TML in the plasma samples.
Methods
Subjects
Convenient blood samples from 79 pregnant women of
an age between 20 and 43 years [25.8 ± 12.8 (SD) years], a
height of 1.67 ± 0.07 (SD) m and a body mass index of
27.8 ± 4.0 (SD) kg/m2 were included in this study . The
plasma samples included those which were collected for
routine blood analysis during hospitalization at the
maternity units of St. Elisabeth and St. Barbara Hospital
in Halle (Saale), Germany at delivery, between October
and December 2008. No exclusion criteria such as gesta-
tional age, medical history, dietary habits or the intake of
nutritional supplements were considered. The study was
approved by the Research Ethics Committee of the hospi-
tal. Sample collection followed ethical principles for med-
ical research according to the World Medical Association
Declaration of Helsinki.
Sample analysis
Plasma (20 μl) was added with methanol containing the
internal standard. A 1100-er series HPLC (Agilent Tech-
nologies, Waldbronn, Germany) equipped with a Kroma-
sil 100 column (5 μm particle size, 125 mm length, 2 mm
internal diameter, CS-Chromatographie Service, Langer-
wehe, Germany) and an API 2000 LC-MS/MS-System
(Applied Biosystems, Darmstadt, Germany) were used
for quantification of free carnitine, acetyl carnitine, pro-
pionyl carnitine, BB and TML. For detection, the analytes
were ionized by positive ion (5500 V) electrospray. As
eluents, methanol and a methanol:water:acetonitrile mix-
ture (50:45:5) were used (Hirche et al., 2007). Total carn-
nitine was caluculated as the sum of free, acetyl and
propionyl carnitine. A full blood count (XE-2100; Sysmex
GmbH, Norderstedt, Germany), including hemoglobin
(Hb), MCV and MCH, was performed at the central labor
of the hospital. Serum ferritin was determined with com-
mercial enzyme linked immune sorbent assay kit (Alpha
Diagnostic International, ELISA Kit Cat. No. 1210, San
Antonio, Texas, USA). Concentration of plasma total iron
was performed with a kit reagent [Quanti Chrom™ Iron
Assay Kit (DIFE-250), Bio Assay Systems, Hayward, CA,
USA].
Statistical methods
Correlation analyses were performed using the Minitab
Statistical Software (Release 13, Minitab Inc., State Col-
lege, PA, USA). R-squared and adjusted R-squared were
calculated with the linear regression tool using ferritin,
TML or BB as predictors and free carnitine or total carni-
tine as responses. Correlations were considered signifi-
cant for P < 0.05.
Results
Concentrations of free carnitine, carnitine esters, total
carnitine and the carnitine precursors TML and BB as
well as parameters of iron status of the subjects are shown
in Table 1. Concentrations of carnitine and the carnitine
precursors as well as iron concentration showed a larger
variation between the subjects than those of MCV, MCH,
Hb and ferritin.
There was a tendency for a positive relationship
between plasma ferritin concentration and plasma con-
centrations of free carnitine (P = 0.09) and total carnitine
(P = 0.06) (Figure 1). There were, however, no correla-
tions between all the other parameters of iron status
(plasma Fe concentration, MCV, MCH, Hb) and plasma
concentrations of free and total carnitine (data not
shown).
There was a significant positive correlation between
plasma concentration of TML and BB (P < 0.001; data not
shown). Moreover, there were significant positive correla-
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cursors TML and BB and plasma concentrations of free
and total carnitine (Figure 2). While the correlation
between TML and carnitine concentration was relatively
weak, although being statistically significant (P < 0.05),
that between BB and carnitine concentration was much
stronger. There were, however, no significant correlations
between parameters of iron status and concentrations of
TML and BB (data not shown).
Discussion
A recent study with a lower number of subjects indicated
that low plasma carnitine concentrations observed in
pregnant women could be due to a low iron status [14].
One aim of the present study was to proof this indication
in a greater number of pregnant women. Therefore, we
considered plasma samples of 79 pregnant women at
delivery. Average plasma total carnitine concentrations at
delivery, being around 15 μmol/l, are in well agreement
with those of our previous study [14] and several other
studies [8-13,15]. Thus, the finding that pregnant women
have a very low carnitine status at delivery is confirmed
by the present study. Plasma carnitine concentrations
below 20 μmol/L have been even considered as a marker
of carnitine deficiency [19] although it is unknown
whether these low carnitine concentrations have adverse
effects on the metabolism of women or their fetuses.
In the present study, we could not support the previous
finding that a low iron status is the main reason for the
low plasma carnitine concentrations observed at delivery.
The correlation between plasma ferritin and carnitine
concentrations in this study was much weaker than that
observed in the previous study [14], and moreover failed
t o  b e  s t a t i s t i c a l l y  s i g n i f i c a n t .  T h e  l a c k  o f  c o r r e l a t i o n s
between other parameters of iron status and plasma car-
nitine concentrations also indicates that an insufficient
iron status can be ruled out as the main reason for low
carnitine concentrations. Although unlikely, we cannot
exclude the possibility that a significant correlation could
not be demonstrated because of the inclusion of pregnant
women with abnormal dietary habits, e.g. intake of nutri-
tional supplements, physical activity preceding delivery,
pathological abnormalities or different gestational ages.
In this study, no subjects were excluded from this study
based on gestational age, dietary habits, physical activity
or medical history.
Table 1: Concentrations of carnitine, carnitine precursors and parameters of iron status in plasma of the subjects (n = 79)
Mean ± SD Minimum - Maximum
Free carnitine, plasma (μmol/l) 12.8 ± 2.91 7.67-22.6
Carnitine esters, plasma (μmol/l) 1.88 ± 0.64 0.92-3.64
Total carnitine, plasma (μmol/l) 14.7 ± 3.34 9.09-25.7
TML, plasma (μmol/l) 0.33 ± 0.12 0.18-0.89
BB, plasma (μmol/l) 0.33 ± 0.10 0.19-0.65
MCV (fl) 89.0 ± 5.09 74.6-100.6
MCH (fmol/l) 1.90 ± 0.13 1.55-2.17
Hb (mmol/l) 7.64 ± 0.77 5.0-9.9
Ferritin, plasma (μg/l) 0.47 ± 0.05 0.38-0.68
Fe, plasma (mg/l) 2.27 ± 1.12 1.03-4.63
Figure 1 Correlation between plasma ferritin concentration and 
plasma concentrations of free carnitine (A) and total carnitine (B).
A
B
y = 0.111 x + 7.63  
R2 = 0.036,  P = 0.092
B
y = 0.139 x + 8.25  
R2 = 0.045, P = 0.062Ringseis et al. BMC Pregnancy and Childbirth 2010, 10:17
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On the other hand, we observed for the first time sig-
nificant correlations between concentrations of the meta-
bolic carnitine precursors TML and BB and plasma
carnitine concentrations. Previously, it has been shown
that the availability of BB in liver and kidneys is limiting
for carnitine biosynthesis in humans while the activity of
BB in these tissues is normally in excess of the amount of
carnitine formed [7]. This means that low plasma con-
centrations of carnitine in pregnant women could be the
result of a diminished carnitine biosynthesis due to the
lack of sufficient BB available as a precursor. This sugges-
tion is supported by the fact that plasma BB concentra-
tions in pregnant women are indeed lower than in non-
pregnant subjects [14,20]. In our previous study, plasma
BB concentrations in women at delivery (0.31 μmol/L)
were similar to those observed in the present study while
they were rising during the lactation period to a level of
0.54 μmol/L at day 28. The increase of plasma BB from
delivery to day 28 of lactation was paralleled by an
increase of plasma carnitine concentration [14].
BB is derived from TML which acts as the first precur-
sor in the carnitine biosynthesis pathway. Accordingly,
the finding of a positive relationship between TML and
BB concentrations is plausible. This correlation indicates
that the low concentration of BB, the direct precursor of
carnitine, is due to a low availability of TML. TML is
formed by methylation of lysine in protein peptide link-
ages and then released upon protein degradation. Indeed,
p l a s m a  c o n c e n t r a t i o n s  o f  T M L  l i k e  t h o s e  o f  B B  a r e
reduced in pregnant women compared to non-pregnant
subjects [14,20]. Diminished plasma TML concentrations
in pregnant women may be the result of a reduced rate of
protein breakdown since gestation is an anabolic state
with an increase in maternal fat and protein stores [21].
Alternatively, the possibility that TML concentration was
due to a reduced methylation of protein bound lysine
cannot be ruled out.
Conclusion
This study does not confirm that low carnitine concen-
trations observed in pregnant women are due to an insuf-
ficient iron status. However, a positive correlation
between plasma concentration of BB and that of carnitine
has been observed. This suggests that low plasma con-
Figure 2 Correlation between plasma concentrations of TML and plasma concentrations of free (A) and total carnitine (B), and between BB 
and plasma concentrations of free (C) and total carnitine (D).
AB
y = 14.88 x + 7.83
R2 = 0.24, P < 0.001
y = 18.05 x + 8.741  
R2 = 0.27, P < 0.001
CD
Fi 2
y = 5.536 x + 10.99
R2 = 0.052, P = 0.042
y = 6.366 x + 12.67
R2 = 0.054, P = 0.041Ringseis et al. BMC Pregnancy and Childbirth 2010, 10:17
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centrations of carnitine in pregnant women may be the
result of a diminished carnitine biosynthesis due to the
lack of sufficient BB available as a precursor.
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